Oakes, Lyman: Is This the Model for Building European Device Companies?

Despite outstanding clinical science, Europe has historically lagged behind the US, if not in medical device innovation, at least in device company creation. A vicious cycle of few start-ups, reluctant VCs, and a poor pool of experienced managers has kept company creation from exploding. But now former merchant bankers turned serial entrepreneurs, Herb Oakes and Dick Lyman, believe they have a better formula for starting device companies in Europe.

Successful device-company creation works in a kind of virtuous circle: physicians or engineers with promising ideas find venture backers who believe in those ideas and fund the launch of a company to bring the innovation to market and who, in turn, after a certain period of time, find seasoned executives to grow the company and realize the potential of the idea.

But that virtuous circle can turn vicious if any of those pieces are missing: if physicians are reluctant to commercialize their ideas, venture sources don't crop up; conversely, if venture sources aren't there, there's no one to fund the companies' creation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By 

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.

Dealmaking Quarterly Statistics, Q1 2025

 
• By 

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.